Filed with ASX · · 3 pages · English
Amplia Therapeutics Ltd. has provided updates on its clinical trials involving its lead drug, narmafotinib, in a recent filing. The ACCENT trial continues with one patient remaining and two patients having completed two years, while the AMPLICITY trial has recorded one confirmed and one unconfirmed partial response. Pre-trial activities for the ACCENT-Mini trial are well advanced, with ethics approval expected soon, and ethics approval has also been submitted for the ovarian cancer PRROSE study.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
22 OCTOBER 2026 ASX RELEASE AMPLIA THERAPEUTICS PROVIDES CLINICAL TRIAL UPDATES HIGHLIGHTS • One patient remains on the ACCENT trial, with 2 patients completing 24 months on study • One patient remains on the AMPLICITY trial with 1 confirmed and 1 unconfirmed partial response (PR) recorded to...
Amplia Therapeutics Ltd. on 6ix
Follow Amplia Therapeutics into a list and get an email when it puts out news.
Follow Amplia Therapeutics